Crossmark Global Holdings Inc. Sells 227 Shares of STERIS plc (NYSE:STE)

Crossmark Global Holdings Inc. lowered its holdings in STERIS plc (NYSE:STE) by 3.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,010 shares of the medical equipment provider’s stock after selling 227 shares during the period. Crossmark Global Holdings Inc.’s holdings in STERIS were worth $1,458,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. West Coast Financial LLC raised its position in shares of STERIS by 2.8% in the third quarter. West Coast Financial LLC now owns 1,640 shares of the medical equipment provider’s stock valued at $398,000 after buying an additional 45 shares in the last quarter. Taylor Frigon Capital Management LLC raised its holdings in STERIS by 0.8% in the 2nd quarter. Taylor Frigon Capital Management LLC now owns 6,175 shares of the medical equipment provider’s stock valued at $1,356,000 after acquiring an additional 46 shares in the last quarter. J.Safra Asset Management Corp lifted its position in shares of STERIS by 77.9% during the 1st quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 53 shares during the period. Mather Group LLC. grew its holdings in shares of STERIS by 7.6% during the 2nd quarter. Mather Group LLC. now owns 763 shares of the medical equipment provider’s stock worth $172,000 after purchasing an additional 54 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of STERIS by 16.5% in the first quarter. EverSource Wealth Advisors LLC now owns 402 shares of the medical equipment provider’s stock worth $82,000 after purchasing an additional 57 shares during the period. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Trading Down 0.2 %

Shares of NYSE STE opened at $222.23 on Thursday. The firm has a 50 day moving average price of $231.12 and a two-hundred day moving average price of $228.20. The stock has a market cap of $21.94 billion, a P/E ratio of 50.74 and a beta of 0.85. STERIS plc has a 52-week low of $195.47 and a 52-week high of $248.24. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.55 and a current ratio of 2.41.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating analysts’ consensus estimates of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The firm had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same quarter in the previous year, the company posted $2.03 EPS. The business’s revenue was up 7.3% on a year-over-year basis. As a group, equities analysts forecast that STERIS plc will post 9.15 EPS for the current year.

STERIS Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be issued a dividend of $0.57 per share. The ex-dividend date of this dividend is Tuesday, November 19th. This represents a $2.28 annualized dividend and a yield of 1.03%. STERIS’s payout ratio is 52.05%.

Insider Transactions at STERIS

In other news, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the sale, the chief financial officer now directly owns 42,930 shares in the company, valued at $10,603,710. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.14% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on STE. Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and raised their target price for the company from $230.00 to $260.00 in a report on Thursday, October 24th. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a report on Wednesday, August 7th. KeyCorp boosted their price target on STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a report on Tuesday, September 3rd. StockNews.com lowered STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Finally, Needham & Company LLC reissued a “hold” rating on shares of STERIS in a report on Friday, November 8th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $253.00.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.